Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 3/24/2025 | $10.00 | Outperform | Oppenheimer |
4 - Quince Therapeutics, Inc. (0001662774) (Issuer)
4 - Quince Therapeutics, Inc. (0001662774) (Issuer)
4 - Quince Therapeutics, Inc. (0001662774) (Issuer)
Quince Therapeutics, Inc. (NASDAQ:QNCX), a biotechnology company focused on acquiring, developing, and commercializing innovative therapeutics that transform patients' lives, today announced that its Board of Directors (the "Board") unanimously approved the adoption of a limited duration stockholder rights plan (the "Rights Plan") and declared a dividend distribution of one preferred share purchase right on each outstanding share of Quince's common stock. The dividend distribution will be made on April 17, 2023, payable to stockholders of record on that date, and is not taxable to stockholders. The Rights Plan is effective immediately and has a one-year duration, expiring on April 5, 2024.
Quince Therapeutics, Inc. (NASDAQ:QNCX), a late-stage biotechnology company dedicated to unlocking the power of a patient's own biology for the treatment of rare diseases, announced the appointment of Dr. William Whitehouse, Honorary Clinical Associate Professor of the School of Medicine at the University of Nottingham, and recently retired Consultant Paediatric Neurologist at Nottingham Children's Hospital, Nottingham University Hospitals NHS Trust, to the company's Scientific Advisory Board (SAB). Dr. Whitehouse joins seven founding members of Quince's SAB comprised of leading experts in biochemistry, neurology, immunology, hematology, pharmacology, and clinical practice. Dr. Mauro Magn
Quince Therapeutics, Inc. (NASDAQ:QNCX), a late-stage biotechnology company developing an innovative drug delivery technology that leverages a patient's own biology to deliver rare disease therapeutics, today announced the appointment of Rajiv Patni, M.D., a biopharma industry veteran and global product development expert, to the company's Board of Directors. "We are pleased to welcome a proven clinical development leader of Dr. Rajiv Patni's caliber to our Board of Directors," said David Lamond, chairperson of Quince's Board of Directors. "With expertise that spans the continuum from translational to registrational studies and regulatory agency negotiation in several rare diseases, we lo
Quince Therapeutics, Inc. (NASDAQ:QNCX), a biotechnology company focused on acquiring, developing, and commercializing innovative therapeutics that transform patients' lives, today announced the appointment of Charles S. Ryan, J.D., Ph.D. as President. In this new position, Dr. Ryan will be responsible for the company's corporate legal activities and intellectual property portfolio, and pending the completion of its planned acquisition of EryDel S.p.A., the international integration of financial and operational activities and ongoing business operations of Quince. Dirk Thye, M.D., Quince's Chief Executive Officer, said, "Charles is a valuable addition to our management team. His considera
Quince Therapeutics, Inc. (NASDAQ:QNCX), a late-stage biotechnology company dedicated to unlocking the power of a patient's own biology for the treatment of rare diseases, today announced that Dirk Thye, M.D., Quince's Chief Executive Officer and Chief Medical Officer, will present at the Citizens Life Sciences Conference taking place in New York City on Wednesday, May 7, 2025 beginning at 3:30 p.m. Eastern Time. A live webcast of the presentation will be accessible on the Events page under the News & Events heading of Quince's Investor Relations website at ir.quincetx.com. An archive of the webcast will be available shortly following the end of the live event. About Quince Therapeutics
Quince Therapeutics, Inc. (NASDAQ:QNCX), a late-stage biotechnology company dedicated to unlocking the power of a patient's own biology for the treatment of rare diseases, today announced that Dirk Thye, M.D., Quince's Chief Executive Officer and Chief Medical Officer, will present at the Jones Healthcare and Technology Innovation Conference on Wednesday, April 9, 2025. A replay of the presentation will be accessible on the Events page under the News & Events heading of Quince's Investor Relations website at ir.quincetx.com. About Quince Therapeutics Quince Therapeutics, Inc. (NASDAQ:QNCX) is a late-stage biotechnology company dedicated to unlocking the power of a patient's own biology f
Phase 3 NEAT clinical trial exceeds 50% enrollment with new study site activations expected to accelerate screenings and randomization Existing cash position of $40.8 million expected to provide operating runway through Phase 3 topline results into 2026 Quince Therapeutics, Inc. (NASDAQ:QNCX), a late-stage biotechnology company dedicated to unlocking the power of a patient's own biology for the treatment of rare diseases, today provided an update on the company's development pipeline and reported financial results for the fiscal year ended December 31, 2024. Dirk Thye, M.D., Quince's Chief Executive Officer and Chief Medical Officer, said, "Our Phase 3 pivotal NEAT clinical trial has exc
SC 13G/A - Quince Therapeutics, Inc. (0001662774) (Subject)
SC 13D - Quince Therapeutics, Inc. (0001662774) (Subject)
SC 13G/A - Quince Therapeutics, Inc. (0001662774) (Subject)
Oppenheimer initiated coverage of Quince Therapeutics with a rating of Outperform and set a new price target of $10.00
4 - Quince Therapeutics, Inc. (0001662774) (Issuer)
4 - Quince Therapeutics, Inc. (0001662774) (Issuer)
4 - Quince Therapeutics, Inc. (0001662774) (Issuer)
SCHEDULE 13G/A - Quince Therapeutics, Inc. (0001662774) (Subject)
DEFA14A - Quince Therapeutics, Inc. (0001662774) (Filer)
DEF 14A - Quince Therapeutics, Inc. (0001662774) (Filer)